India, July 30 -- Shares of BioNexus Gene Lab Corp. (BGLC) surged over 87% on Wednesday morning after the company announced a strategic alliance with Fidelion Diagnostics, a Singapore-based precision oncology firm.
The deal, described by the companies as a "DeepSeek-class leap" in cancer diagnostics, will see BioNexus acquire an equity stake in Fidelion and secure exclusive commercial rights to Fidelion's VitaGuard minimal residual disease (MRD) liquid biopsy platform across Southeast Asia.
In return, Fidelion will receive an equity investment and a license fee from BGLC, aligning the two firms for long-term collaborative growth.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The stock is currently ...